Movatterモバイル変換


[0]ホーム

URL:


US20020064546A1 - Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor - Google Patents

Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
Download PDF

Info

Publication number
US20020064546A1
US20020064546A1US08/928,049US92804997AUS2002064546A1US 20020064546 A1US20020064546 A1US 20020064546A1US 92804997 AUS92804997 AUS 92804997AUS 2002064546 A1US2002064546 A1US 2002064546A1
Authority
US
United States
Prior art keywords
peg
linkages
reaction product
amine
crosslinked
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US08/928,049
Inventor
J. Milton Harris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Debio Recherche Pharmaceutique SA
Nektar Therapeutics
Original Assignee
Debio Recherche Pharmaceutique SA
Shearwater Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=25455637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20020064546(A1)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Debio Recherche Pharmaceutique SA, Shearwater CorpfiledCriticalDebio Recherche Pharmaceutique SA
Priority to US08/928,049priorityCriticalpatent/US20020064546A1/en
Priority to JP2000511806Aprioritypatent/JP4083384B2/en
Priority to AU60293/98Aprioritypatent/AU6029398A/en
Priority to EP98903545Aprioritypatent/EP1019446B2/en
Priority to ES98903545Tprioritypatent/ES2281925T5/en
Priority to PCT/US1998/000920prioritypatent/WO1999014259A1/en
Priority to PT98903545Tprioritypatent/PT1019446E/en
Priority to DE69837443Tprioritypatent/DE69837443T3/en
Priority to CA002303365Aprioritypatent/CA2303365C/en
Priority to DK98903545.6Tprioritypatent/DK1019446T4/en
Priority to AT98903545Tprioritypatent/ATE358150T1/en
Assigned to SHEARWATER POLYMERS, INC.reassignmentSHEARWATER POLYMERS, INC.ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).Assignors: HARRIS, J. MILTON
Assigned to SHEARWATER CORPORATIONreassignmentSHEARWATER CORPORATIONCHANGE OF NAME (SEE DOCUMENT FOR DETAILS).Assignors: SHEARWATER POLYMERS, INC.
Assigned to DEBIO RECHERCHE PHARMACEUTIQUE S.A.reassignmentDEBIO RECHERCHE PHARMACEUTIQUE S.A.ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).Assignors: SHEARWATER POLYMERS, INC.
Publication of US20020064546A1publicationCriticalpatent/US20020064546A1/en
Assigned to NEKTAR THERAPEUTICS AL, CORPORATIONreassignmentNEKTAR THERAPEUTICS AL, CORPORATIONCHANGE OF NAME (SEE DOCUMENT FOR DETAILS).Assignors: SHEARWATER CORPORATION
Priority to US10/684,893prioritypatent/US7964217B2/en
Assigned to NEKTAR THERAPEUTICS AL, CORPORATIONreassignmentNEKTAR THERAPEUTICS AL, CORPORATIONRE-RECORD TO REMOVE SIX APPLICATION AND PATENT NUMBERS INCORRECTLY INCLUDED ON PREVIOUSLY RECORDED DOCUMENT AT REEL 013467 FRAME 0564.Assignors: SHEARWATER CORPORATION
Assigned to NEKTAR THERAPEUTICSreassignmentNEKTAR THERAPEUTICSMERGER (SEE DOCUMENT FOR DETAILS).Assignors: NEKTAR THERAPEUTICS AL, CORPORATION
Abandonedlegal-statusCriticalCurrent

Links

Images

Classifications

Definitions

Landscapes

Abstract

This invention relates to hydrolytically degradable gels of crosslinked poly(ethylene) glycol (PEG) structures. Addition of water causes these crosslinked structures to swell and become hydrogels. The hydrogels can be prepared by reacting two different PEG derivatives containing functional moieties at the chain ends that react with each other to form new covalent linkages between polymer chains. The PEG derivatives are chosen to provide covalent linkages within the crosslinked structure that are hydrolytically degradable. Hydrolytic degradation can provide for dissolution of the gel components and for controlled release of trapped molecules, including drugs. Reagents other than PEG can be avoided. The hydrolysis rates can be controlled by varying atoms adjacent to the hydrolytically degradable functional groups to provide substantially precise control for drug delivery in vivo.

Description

Claims (32)

What is claimed is:
1. A crosslinked polymeric structure comprising poly(ethylene glycol) (PEG) polymers in the substantial absence of non-PEG polymers and having linkages between said PEG polymers wherein at least some of said linkages comprise hydrolytically unstable linkages.
2. The crosslinked polymeric structure ofclaim 1 wherein said hydrolytically unstable linkages are sufficient to cause said crosslinked polymeric structure to degrade by hydrolysis in aqueous solution.
3. The crosslinked polymeric structure ofclaim 1 wherein said structure forms a PEG hydrogel in aqueous solution that is subject to hydrolysis.
4. The crosslinked polymeric structure ofclaim 3 wherein the PEG hydrogel formed therefrom has a rate of hydrolysis that is determined at least in part by the structure of said linkages between said PEG polymers.
5. The crosslinked polymeric structure ofclaim 4 wherein said linkages comprise one or more methylene groups in proximity to said hydrolytically unstable linkages sufficient to determine at least in part said rate of hydrolysis of said hydrolytically unstable linkages.
6. The crosslinked polymeric structure ofclaim 5 wherein said hydrolysis rate is decreased as the number of said methylene groups is increased.
7. The crosslinked polymeric structure ofclaim 1 wherein said hydrolytically unstable linkages comprise linkages selected from the group consisting of esters, imines, hydrazones, acetals, orthoesters, peptides, and oligonucleotides.
8. The crosslinked polymeric structure ofclaim 7 wherein said hydrolytically unstable ester linkages comprise linkages selected from the group consisting of carboxylate esters and phosphate esters.
9. The crosslinked polymeric structure ofclaim 8 wherein said hydrolytically unstable carboxylate ester linkages are the reaction product of a PEG alcohol and a PEG carboxylic acid and wherein said hydrolytically unstable phosphate ester linkages are the reaction product of a PEG alcohol and a PEG phosphate.
10. The crosslinked polymeric structure ofclaim 7 wherein said imines are the reaction product of an amine and an aldehyde, wherein said hydrazones are the reaction product of a hydrazide and an aldehyde, wherein said acetals are the reaction product of an aldehyde and an alcohol, wherein said orthoesters are the reaction product of a formate and an alcohol, wherein said hydrolytically unstable peptide linkages comprise linkages selected from the group consisting of peptide linkages that are the reaction product of amines and PEG-peptide conjugates terminated with carboxyl and peptide linkages that are the reaction product of a carboxylic acid and PEG-peptide conjugates terminated with amine, and wherein said hydrolytically unstable oligonucleotide linkages are the reaction product of a phosphoramidite with a 5′-hydroxyl-terminated PEG oligonucleotide.
11. The crosslinked polymeric structure ofclaim 1 wherein said structure also comprises hydrolytically stable linkages that do not degrade in aqueous solution.
12. The crosslinked polymeric structure ofclaim 11 wherein said hydrolytically stable linkages comprise linkages selected from the group consisting of amides, urethanes, ureas, amines, and sulfonamides.
13. The crosslinked polymeric structure ofclaim 12 wherein said amide linkages are the reaction product of an ester and an amine, wherein said urethane linkages are the reaction product of an isocyanate and an alcohol, wherein said urea linkages are the reaction product of an isocyanate and an amine, wherein said hydrolytically stable amine linkages are selected from the group consisting of the reaction product of an aldehyde and an amine in the presence of a reducing agent and the reaction product of an epoxide and an amine, and wherein said sulfonamide linkages are the reaction product of an amine and a sulfonate ester.
14. The crosslinked polymeric structure ofclaim 13 wherein said amide linkages are the reaction product of a carboxylate ester and an amine.
15. A drug delivery system comprising a poly(ethylene glycol) hydrogel made from the crosslinked polymeric structure ofclaim 1.
16. A poly(ethylene glycol) (PEG) hydrogel comprising PEG polymers in the substantial absence of non-PEG polymers and having linkages between said PEG polymers wherein at least some of said linkages are hydrolyzable under hydrolysis conditions, said hydrolyzable linkages comprising linkages selected from the group consisting of esters, imines, hydrazones, acetals, orthoesters, peptides, and oligonucleotides.
17. A drug delivery system comprising the PEG hydrogel ofclaim 15.
18. A crosslinked polymeric structure comprising poly(ethylene glycol) (PEG) and having a formula selected from the group consisting of:
{R[CH2—O-PEG-W-PEG-W-]p}m{R[CH2—O-PEG-X-PEG-W-PEG-X-]p}m{R[CH2—O-PEG-X-R′-W-PEG-W-R′-X-]p}m
wherein m means “matrix” and indicates that the crosslinked structure is a solid aggregate; p is from about 3 to 10 and indicates the number of arms on the polymers forming said crosslinked structure; R is a central branching moiety suitable for making multiarmed PEGs; R′ is a hydrocarbon fragment having from about 1 to 10 carbons; W is a hydrolytically unstable linkage comprising linkages selected from the group consisting of esters, imines, hydrazones, acetals, orthoesters, peptides, and oligonucleotides; and X is a hydrolytically stable linkage comprising linkages selected from the group consisting of amides, urethanes, ureas, amines, and sulfonamides.
19. The crosslinked polymeric structure ofclaim 18 wherein R is a moiety selected from the group consisting of glycerol, glycerol oligomers, pentaerythritol, sorbitol, trimethyolpropane, and di(trimethylolpropane).
20. The crosslinked polymeric structure ofclaim 18 wherein said hydrolytically unstable linkages W comprise carboxylate ester linkages that are the reaction product of an alcohol and a carboxylic acid; phosphate ester linkages that are the reaction product of an alcohol and a phosphate, imine linkages that are the reaction product of an amine and an aldehyde; hydrazones linkages that are the reaction product of a hydrazide and an aldehyde; acetal linkages that are the reaction product of an aldehyde and an alcohol; orthoester linkages that are the reaction product of a formate and an alcohol; peptide linkages that comprise linkages selected from the group consisting of peptide linkages that are the reaction product of amines and PEG-peptide conjugates terminated with carboxyl and peptide linkages that are the reaction product of a carboxylic acid and PEG-peptide conjugates terminated with amine; and oligonucleotide linkages that are the reaction product of a phosphoramidite with a 5′-hydroxyl-terminated PEG oligonucleotide.
21. The crosslinked polymeric structure ofclaim 18 wherein said hydrolytically stable linkages X comprise amide linkages that are the reaction product of an ester and an amine; urethane linkages that are the reaction product of an isocyanate and an alcohol; urea linkages that are the reaction product of an isocyanate and an amine; amine linkages that are selected from the group consisting of the reaction product of an aldehyde and an amine in the presence of a reducing agent and the reaction product of an epoxide and an amine; and sulfonamide linkages that are the reaction product of an amine and a sulfonate ester.
22. The crosslinked polymeric structure ofclaim 21 wherein said amide linkages are the reaction product of a carboxylate ester and an amine.
23. A drug delivery system comprising a poly(ethylene glycol) hydrogel made from the crosslinked polymeric structure ofclaim 18.
24. A crosslinked polymeric structure comprising poly(ethylene glycol) (PEG) and having the formula:
{R[CH2—O-PEG-O2C—(CH2)n—O-PEG-O(CH2)n—CO2—]p}m
wherein m means “matrix” and indicates that the crosslinked structure is a solid aggregate; p is from about 3 to 10 and indicates the number of arms on the polymers forming said crosslinked structure; R is a moiety selected from the group consisting of glycerol, glycerol oligomers, pentaerythritol, sorbitol, trimethyolpropane, and di(trimethylolpropane); and wherein n is from about 1 to 10.
25. A crosslinked polymeric structure comprising poly(ethylene glycol) (PEG) and having the formula:
{CH3C[CH2—O-PEG-O2C—(CH2)n—O-PEG-O(CH2)n—CO2—]p}m
wherein m means “matrix” and indicates that the crosslinked structure is a solid aggregate, and wherein n is from about 1 to 10.
26. The crosslinked polymeric structure ofclaim 25 wherein when n equals 2, then the ester linkages have a hydrolysis half life of about 4 days at pH 7 and 37 degrees Centrigrade, and wherein when n equals 3, then the ester linkages have a hydrolysis half life of about 43 days at pH 7 and 37 degrees Centrigrade.
27. A method of making a crosslinked polymeric structure comprising poly(ethylene glycol) (PEG) polymers in the substantial absence of non-PEG polymers and having linkages between said PEG polymers wherein at least some of said linkages comprise hydrolytically unstable linkages, said method comprising reacting a linear poly(ethylene glycol) (PEG) with a branched PEG to provide a crosslinked structure having linkages between said PEG polymers wherein at least some of said linkages comprise hydrolyzable linkages.
28. The method ofclaim 27 wherein the step of reacting a linear PEG with a branched PEG includes the steps of separately injecting the linear PEG and the branched PEG into a living organism or into a substance taken from a living organism in close proximity in time and space and reacting the linear and branched PEGs in vivo to form a hydrogel.
29. A method for delivering biologically active substances to a living organism or to a substance taken from a living organism comprising mixing at least one biologically active substance with a linear PEG or a branched PEG as set forth inclaim 28, separately injecting the linear PEG and the branched PEG into a living organism or into a substance taken from a living organism in close proximity in time and space, reacting the linear and branched PEGs in vivo to form a degradable hydrogel matrix in which the biologically active substance is trapped, and subjecting the hydrogel to hydrolysis to degrade the hydrogel and allow the biologically active substances to be delivered.
30. A method for making a crosslinked polymeric structure comprising reacting. a linear poly(ethylene glycol) (PEG) polymer of the formula Z-PEG-Z with a branched PEG polymer of the formula R(CH2—O-PEG-Y)pto provide a crosslinked structure of the formula {R[CH2—O-PEG-W-PEG-]p}m, wherein m means “matrix” and indicates that the crosslinked structure is a solid aggreagte; p is from about 3 to 10 and indicates the number of arms on the polymers forming said crosslinked structure; R is a central branching moiety suitable for making multiarmed PEGs, and wherein Z reacts with Y to form the hydrolytically unstable group W, and Z and Y are selected from the group consisting of alcohols, carboxylic acids, amines, aldehydes, hydrazides, aldehydes, phosphate, formate, PEG-peptide terminated with carboxyl, PEG-peptide terminated with amine, PEG phosphoramidite, and 5′-hydroxyl-terminated PEG oligonucleotide, and wherein W is selected from the group consisting of esters, imines, hydrazones, acetals, orthoesters, peptides, and oligonucleotides.
31. A method for making a crosslinked polymeric structure comprising reacting a linear poly(ethylene glycol) (PEG) with a branched PEG polymer according to the following equation:
U-PEG-W-PEG-U+R(CH2—O-PEG-V)p→→{[CH2—O-PEG-X-PEG-W-PEG-X-]p}m
wherein W is selected from the group consisting of esters, imines, hydrazones, acetals, orthoesters, peptides, and oligonucleotides; wherein U reacts with V to form X, and U and V are selected from the group consisting of active esters, amine, isocyanate, aldehyde, epoxide, and sulfonate ester; wherein X is selected from the group consisting of amides, urethanes, ureas, amines, and sulfonamides; and wherein m means “matrix” and indicates that the crosslinked structure is a solid aggreagte; p is from about 3 to 10 and indicates the number of arms on the polymers forming said crosslinked structure; and R is a central branching moiety suitable for making multiarmed PEGs.
32. A method for making a crosslinked polymeric structure comprising reacting a linear poly(ethylene glycol) (PEG) with a branched PEG polymer according to the following equation:
U-R′-W-PEG-W-R′-U+R(CH2—O-PEG-V)p→{R[CH2—O-PEG-X-R′-W-PEG-W-R′-X]p}m
wherein R′ is a hydrocarbon fragment having from about 1 to 10 carbons; wherein W is selected from the group consisting of esters, imines, hydrazones, acetals, orthoesters, peptides, and oligonucleotides; wherein U reacts with V to form X, and U and V are selected from the group consisting of active esters, amine, isocyanate, aldehyde, epoxide, and sulfonate ester; wherein X is selected from the group consisting of amides, urethanes, ureas, amines, and sulfonamides; and wherein m means “matrix” and indicates that the crosslinked structure is a solid aggreagte; p is from about 3 to 10 and indicates the number of arms on the polymers forming said crosslinked structure; and R is a central branching moiety suitable for making multiarmed PEGs.
US08/928,0491996-09-131997-09-12Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors thereforAbandonedUS20020064546A1 (en)

Priority Applications (12)

Application NumberPriority DateFiling DateTitle
US08/928,049US20020064546A1 (en)1996-09-131997-09-12Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
AT98903545TATE358150T1 (en)1997-09-121998-01-23 DEGRADABLE POLYETHYLENE GLYCOL HYDRGELS WITH CONTROLLED HALF-LIFE AND THEIR PREPRODUCTS
AU60293/98AAU6029398A (en)1997-09-121998-01-23Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
CA002303365ACA2303365C (en)1997-09-121998-01-23Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
EP98903545AEP1019446B2 (en)1997-09-121998-01-23Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
ES98903545TES2281925T5 (en)1997-09-121998-01-23 Degradable polyethylene glycol hydrogels with controlled half-life and precursors thereof
PCT/US1998/000920WO1999014259A1 (en)1997-09-121998-01-23Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
PT98903545TPT1019446E (en)1997-09-121998-01-23Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
DE69837443TDE69837443T3 (en)1997-09-121998-01-23 DEGRADABLE POLYETHYLENEGLYCOLHYDROGELE WITH CONTROLLED HALF TIME AND ITS PREPARED PRODUCTS
JP2000511806AJP4083384B2 (en)1997-09-121998-01-23 Degradable poly (ethylene glycol) hydrogel with controlled half-life and precursor thereof
DK98903545.6TDK1019446T4 (en)1997-09-121998-01-23 Degradable poly (ethylene glycol) hydrogels with controlled half-life and precursors thereto
US10/684,893US7964217B2 (en)1996-09-132003-10-14Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
US2606696P1996-09-131996-09-13
US08/928,049US20020064546A1 (en)1996-09-131997-09-12Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor

Related Child Applications (1)

Application NumberTitlePriority DateFiling Date
US10/684,893ContinuationUS7964217B2 (en)1996-09-132003-10-14Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor

Publications (1)

Publication NumberPublication Date
US20020064546A1true US20020064546A1 (en)2002-05-30

Family

ID=25455637

Family Applications (2)

Application NumberTitlePriority DateFiling Date
US08/928,049AbandonedUS20020064546A1 (en)1996-09-131997-09-12Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
US10/684,893Expired - Fee RelatedUS7964217B2 (en)1996-09-132003-10-14Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor

Family Applications After (1)

Application NumberTitlePriority DateFiling Date
US10/684,893Expired - Fee RelatedUS7964217B2 (en)1996-09-132003-10-14Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor

Country Status (11)

CountryLink
US (2)US20020064546A1 (en)
EP (1)EP1019446B2 (en)
JP (1)JP4083384B2 (en)
AT (1)ATE358150T1 (en)
AU (1)AU6029398A (en)
CA (1)CA2303365C (en)
DE (1)DE69837443T3 (en)
DK (1)DK1019446T4 (en)
ES (1)ES2281925T5 (en)
PT (1)PT1019446E (en)
WO (1)WO1999014259A1 (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20030108917A1 (en)*2001-09-012003-06-12Nam HuhMethod for manufacturing hydrogel biochip by using star-like polyethylene glycol derivative having epoxy group
US20030202955A1 (en)*1996-11-062003-10-30Debio Recherche Pharmaceutique S.A.Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
WO2004022629A2 (en)*2002-09-092004-03-18Nektar Therapeutics Al, CorporationMethod for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid
US20040231886A1 (en)*2003-05-202004-11-25Boggs David W.PCB design and method for providing vented blind vias
US20070213683A1 (en)*1998-11-062007-09-13Neomend, Inc.Systems, methods, and compositions for prevention of tissue adhesion
US20090215923A1 (en)*2008-02-132009-08-27Hyperbranch Medical Technology, Inc.Crosslinked Polyalkyleneimine Hydrogels with Tunable Degradation Rates
US20100268750A1 (en)*2007-11-082010-10-21Koninklijke Philips Electronics N.V.Method and electronic device for managing content
US8105570B2 (en)2001-12-142012-01-31The University Of WyomingMethods and compositions for controlled release of drugs
US8440309B2 (en)2011-01-312013-05-14Confluent Surgical, Inc.Crosslinked polymers with the crosslinker as therapeutic for sustained release
US9061137B2 (en)*2012-10-102015-06-23Korea Institute Of Science And TechnologyNerve electrode provided with anti-inflammatory drug and method of manufacturing the same
US20150202305A1 (en)*2012-09-072015-07-23The Regents Of The University Of CaliforniaMethod of creating hydrogels through oxime bond fomration
WO2017200818A1 (en)*2016-05-162017-11-23The Trustees Of Columbia University In The City Of New YorkCoatings and methods for infection-resistant medical devices
US9855340B2 (en)2012-10-112018-01-02Ascendis Pharma A/SHydrogel prodrugs
US10806144B2 (en)2011-11-032020-10-20The Trustees Of Columbia University In The City Of New YorkComposition with sustained antimicrobial activity
US20210162092A1 (en)*2018-08-102021-06-03Shanghai Ruining Biotechnology Co. LtdMedical hydrogel
US11041052B2 (en)2016-03-312021-06-22Nof CorporationBiodegradable hydrogel having cyclic benzylidene acetal structure
CN114767920A (en)*2022-05-132022-07-22中国科学院长春应用化学研究所 A kind of polyethylene glycol based adhesive and its preparation method and application
WO2022170681A1 (en)*2021-02-092022-08-18北京光瓴医疗科技有限公司Degradable two-component hydrogel, preparation method therefor and use thereof

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US6566406B1 (en)*1998-12-042003-05-20Incept, LlcBiocompatible crosslinked polymers
WO1998012274A1 (en)1996-09-231998-03-26Chandrashekar PathakMethods and devices for preparing protein concentrates
US8003705B2 (en)1996-09-232011-08-23Incept LlcBiocompatible hydrogels made with small molecule precursors
US6371975B2 (en)1998-11-062002-04-16Neomend, Inc.Compositions, systems, and methods for creating in situ, chemically cross-linked, mechanical barriers
US20030191496A1 (en)1997-03-122003-10-09Neomend, Inc.Vascular sealing device with microwave antenna
US7642323B2 (en)1997-11-062010-01-05Nektar TherapeuticsHeterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US6448369B1 (en)1997-11-062002-09-10Shearwater CorporationHeterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US6514534B1 (en)1998-08-142003-02-04Incept LlcMethods for forming regional tissue adherent barriers and drug delivery systems
US6458147B1 (en)1998-11-062002-10-01Neomend, Inc.Compositions, systems, and methods for arresting or controlling bleeding or fluid leakage in body tissue
US6994686B2 (en)1998-08-262006-02-07Neomend, Inc.Systems for applying cross-linked mechanical barriers
US6899889B1 (en)1998-11-062005-05-31Neomend, Inc.Biocompatible material composition adaptable to diverse therapeutic indications
US7279001B2 (en)1998-11-062007-10-09Neomend, Inc.Systems, methods, and compositions for achieving closure of vascular puncture sites
US6949114B2 (en)1998-11-062005-09-27Neomend, Inc.Systems, methods, and compositions for achieving closure of vascular puncture sites
US6830756B2 (en)1998-11-062004-12-14Neomend, Inc.Systems, methods, and compositions for achieving closure of vascular puncture sites
EP2311895B1 (en)1999-02-012017-04-12Eidgenössische Technische Hochschule ZürichBiomaterials formed by nucleophilic addition reaction to conjugated unsaturated groups
US6958212B1 (en)1999-02-012005-10-25Eidgenossische Technische Hochschule ZurichConjugate addition reactions for the controlled delivery of pharmaceutically active compounds
US7192713B1 (en)1999-05-182007-03-20President And Fellows Of Harvard CollegeStabilized compounds having secondary structure motifs
US7008635B1 (en)1999-09-102006-03-07Genzyme CorporationHydrogels for orthopedic repair
JP4344110B2 (en)*1999-10-082009-10-14ネクター セラピューティックス エイエル,コーポレイション Heterobifunctional polyethylene glycol derivatives and methods for their preparation
US6413507B1 (en)*1999-12-232002-07-02Shearwater CorporationHydrolytically degradable carbamate derivatives of poly (ethylene glycol)
JP2003520210A (en)*2000-01-052003-07-02イマレックス セラピューティクス, インコーポレイテッド Pharmaceutical formulations for delivery of drugs with low water solubility
US7291673B2 (en)2000-06-022007-11-06Eidgenossiche Technische Hochschule ZurichConjugate addition reactions for the controlled delivery of pharmaceutically active compounds
EP1355965B1 (en)2000-10-192012-09-19Ecole Polytechnique Fédérale de Lausanne (EPFL)Method of synthesizing block copolymers for multifunctional self-assembled systems
US7829074B2 (en)2001-10-182010-11-09Nektar TherapeuticsHydroxypatite-targeting poly(ethylene glycol) and related polymers
US7214660B2 (en)2001-10-102007-05-08Neose Technologies, Inc.Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7157277B2 (en)2001-11-282007-01-02Neose Technologies, Inc.Factor VIII remodeling and glycoconjugation of Factor VIII
US7795210B2 (en)2001-10-102010-09-14Novo Nordisk A/SProtein remodeling methods and proteins/peptides produced by the methods
US7173003B2 (en)2001-10-102007-02-06Neose Technologies, Inc.Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
EP2305314B1 (en)2001-10-102015-12-23ratiopharm GmbHRemodelling and glycoconjugation of antibodies
US7045552B2 (en)*2002-09-272006-05-16Trimeris, Inc.Pharmaceutical composition for improved administration of HIV gp41-derived peptides, and its use in therapy
NZ542094A (en)2003-03-142008-12-24Neose Technologies IncBranched polymer conjugates comprising a peptide and water-soluble polymer chains
CA2522345A1 (en)2003-04-092004-11-18Neose Technologies, Inc.Glycopegylation methods and proteins/peptides produced by the methods
US8791070B2 (en)2003-04-092014-07-29Novo Nordisk A/SGlycopegylated factor IX
AU2004240553A1 (en)2003-05-092004-12-02Neose Technologies, Inc.Compositions and methods for the preparation of human growth hormone glycosylation mutants
US9005625B2 (en)2003-07-252015-04-14Novo Nordisk A/SAntibody toxin conjugates
ES2586387T3 (en)2003-11-052016-10-14Dana-Farber Cancer Institute, Inc. Suitable alpha helical peptides to activate or inhibit cell death
US8633157B2 (en)2003-11-242014-01-21Novo Nordisk A/SGlycopegylated erythropoietin
US20080305992A1 (en)2003-11-242008-12-11Neose Technologies, Inc.Glycopegylated erythropoietin
US20060040856A1 (en)2003-12-032006-02-23Neose Technologies, Inc.Glycopegylated factor IX
US7956032B2 (en)2003-12-032011-06-07Novo Nordisk A/SGlycopegylated granulocyte colony stimulating factor
CA2551082A1 (en)*2004-01-072005-07-28Trimeris, Inc.Hiv gp41 hr2-derived synthetic peptides, and their use in therapy to inhibit transmission of human immunodeficiency virus
AU2005206796B2 (en)2004-01-082011-06-16Ratiopharm GmbhO-linked glycosylation of peptides
ES2299776T3 (en)2004-06-162008-06-01Straumann Holding Ag BARRIER MEMBRANE.
US7282584B2 (en)2004-06-162007-10-16Straumann Holding AgMethylene blue
EP1771066A2 (en)2004-07-132007-04-11Neose Technologies, Inc.Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
EP1799249A2 (en)2004-09-102007-06-27Neose Technologies, Inc.Glycopegylated interferon alpha
DK2586456T3 (en)2004-10-292016-03-21Ratiopharm GmbhConversion and glycopegylation of fibroblast growth factor (FGF)
AU2006203792B2 (en)2005-01-102011-11-03Ratiopharm GmbhGlycopegylated Granulocyte Colony Stimulating Factor
AU2006213822B2 (en)2005-02-092011-05-26Covidien LpSynthetic sealants
US7517914B2 (en)2005-04-042009-04-14Boston Scientificscimed, Inc.Controlled degradation materials for therapeutic agent delivery
WO2006121569A2 (en)2005-04-082006-11-16Neose Technologies, Inc.Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
EP1891231A4 (en)2005-05-252011-06-22Novo Nordisk As FACTOR IX GLYCOPEGYL
WO2006127910A2 (en)2005-05-252006-11-30Neose Technologies, Inc.Glycopegylated erythropoietin formulations
EP1891141B1 (en)2005-05-312016-11-16Ecole Polytechnique Fédérale de Lausanne (EPFL)Triblock copolymers for cytoplasmic delivery of gene-based drugs
US8367096B2 (en)2005-07-192013-02-05Boston Scientific Scimed, Inc.Polymers having covalently bound therapeutic agents
US20070105755A1 (en)2005-10-262007-05-10Neose Technologies, Inc.One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en)2005-11-032009-02-19Neose Technologies, Inc.Nucleotide Sugar Purification Using Membranes
EP1960447A4 (en)2005-12-082010-12-01Tyco HealthcareBiocompatible surgical compositons
CA2651793C (en)2006-02-022015-07-07Trimeris, Inc.Hiv fusion inhibitor peptides with improved biological properties
US7597882B2 (en)2006-04-242009-10-06Incept LlcProtein crosslinkers, crosslinking methods and applications thereof
US7960498B2 (en)*2006-06-302011-06-14Actamax Surgical Materials, LlcTissue adhesives with modified elasticity
CN101516388B (en)2006-07-212012-10-31诺和诺德公司 Glycosylation of peptides via O-linked glycosylation sequences
US8969532B2 (en)2006-10-032015-03-03Novo Nordisk A/SMethods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
EP2068907B1 (en)2006-10-042017-11-29Novo Nordisk A/SGlycerol linked pegylated sugars and glycopeptides
PL2118123T3 (en)2007-01-312016-06-30Dana Farber Cancer Inst IncStabilized p53 peptides and uses thereof
US20090227689A1 (en)*2007-03-052009-09-10Bennett Steven LLow-Swelling Biocompatible Hydrogels
US20090227981A1 (en)*2007-03-052009-09-10Bennett Steven LLow-Swelling Biocompatible Hydrogels
JP5052919B2 (en)*2007-03-082012-10-17成均▲館▼大學校 産學協力團 PH and temperature sensitive block copolymer hydrogel
EP3159352B1 (en)2007-03-282023-08-02President and Fellows of Harvard CollegeStitched polypeptides
WO2008124406A2 (en)2007-04-032008-10-16Neose Technologies, Inc.Methods of treatment using glycopegylated g-csf
CN101678125A (en)*2007-04-032010-03-24特里梅里斯公司Novel formulations for delivery of antiviral peptide therapeutics
CN101778859B (en)2007-06-122014-03-26诺和诺德公司Improved process for the production of nucleotide sugars
US9125807B2 (en)*2007-07-092015-09-08Incept LlcAdhesive hydrogels for ophthalmic drug delivery
US8067028B2 (en)*2007-08-132011-11-29Confluent Surgical Inc.Drug delivery device
US8207112B2 (en)2007-08-292012-06-26Biogenerix AgLiquid formulation of G-CSF conjugate
WO2009042194A2 (en)*2007-09-252009-04-02Trimeris, Inc.Methods of synthesis for therapeuthic anti-hiv peptides
JP5150297B2 (en)*2008-02-142013-02-20ネクター セラピューティックス エイエル,コーポレイション Heterobifunctional polyethylene glycol derivatives and methods for their preparation
DK2257311T3 (en)2008-02-272014-06-30Novo Nordisk As Conjugated Factor VIII Molecules
AU2009294875C1 (en)2008-09-222015-05-14Aileron Therapeutics, Inc.Methods for preparing purified polypeptide compositions
US9271929B2 (en)2008-11-252016-03-01École Polytechnique Fédérale De Lausanne (Epfl)Block copolymers and uses thereof
JP2012515172A (en)2009-01-142012-07-05エルロン・セラピューティクス・インコーポレイテッド Peptidomimetic macrocycle
CA2750242C (en)2009-02-122018-05-22Incept, LlcDrug delivery through hydrogel plugs
RU2589254C2 (en)2009-06-092016-07-10ПРОЛОНГ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСиHaemoglobin composition
WO2011012718A1 (en)2009-07-312011-02-03Ascendis Pharma AsProdrugs comprising an insulin linker conjugate
WO2011012715A1 (en)*2009-07-312011-02-03Ascendis Pharma AsBiodegradable polyethylene glycol based water-insoluble hydrogels
EP2459171B1 (en)2009-07-312017-06-21Sanofi-Aventis Deutschland GmbHLong acting insulin composition
CA2774973A1 (en)2009-09-222011-03-31Aileron Therapeutics, Inc.Peptidomimetic macrocycles
AU2010311421B2 (en)2009-10-292014-11-20Ascendis Pharma A/SSterilization of biodegradable hydrogels
JP5820815B2 (en)2009-12-152015-11-24インセプト・リミテッド・ライアビリティ・カンパニーIncept,Llc Implants and biodegradable fiducial markers
US8524215B2 (en)*2010-08-022013-09-03Janssen Biotech, Inc.Absorbable PEG-based hydrogels
WO2012021874A1 (en)2010-08-132012-02-16Aileron Therapeutics, Inc.Peptidomimetic macrocycles with thioether linkers
EP2438930A1 (en)2010-09-172012-04-11Sanofi-Aventis Deutschland GmbHProdrugs comprising an exendin linker conjugate
EP2637680B1 (en)2010-11-122017-03-01Dana-Farber Cancer Institute, Inc.Cancer therapies
US10226417B2 (en)2011-09-162019-03-12Peter JarrettDrug delivery systems and applications
EP2768518A4 (en)2011-10-182015-05-27Aileron Therapeutics Inc PEPTIDOMIMETIC MACROCYCLES
US9205150B2 (en)2011-12-052015-12-08Incept, LlcMedical organogel processes and compositions
CA2862391C (en)2011-12-292023-10-10Loren D. WalenskyStabilized antiviral fusion helices
CN104159595A (en)2012-02-152014-11-19爱勒让治疗公司Peptidomimetic macrocycles
JP6450192B2 (en)2012-02-152019-01-09エイルロン セラピューティクス,インコーポレイテッド Triazole-bridged and thioether-bridged peptidomimetic macrocycles
JP5953459B2 (en)*2012-03-272016-07-20ネクター セラピューティクス Heterobifunctional polyethylene glycol derivatives and methods for their preparation
US9395468B2 (en)2012-08-272016-07-19Ocular Dynamics, LlcContact lens with a hydrophilic layer
SI2920197T1 (en)2012-09-262021-08-31President And Fellows Of Harvard CollegeProline-locked stapled peptides and uses thereof
WO2014071241A1 (en)2012-11-012014-05-08Aileron Therapeutics, Inc.Disubstituted amino acids and methods of preparation and use thereof
EP2991665A4 (en)2013-03-132016-11-09Harvard College AGRAFES AND SUTURE POLYPEPTIDES AND USES THEREOF
EP2970392B1 (en)2013-03-152019-07-10Dana-Farber Cancer Institute, Inc.Stabilized sos1 peptides
WO2014144768A2 (en)2013-03-152014-09-18Dana-Farber Cancer Institute, Inc.Bh4 stabilized peptides and uses thereof
US10308926B2 (en)2013-03-152019-06-04Dana-Farber Cancer Institute, Inc.Stablized EZH2 peptides
CN105492460A (en)2013-06-142016-04-13哈佛大学的校长及成员们Stabilized polypeptide insulin receptor modulators
US10711106B2 (en)2013-07-252020-07-14The University Of ChicagoHigh aspect ratio nanofibril materials
WO2015073758A1 (en)2013-11-152015-05-21Ocular Dynamics, LlcContact lens with a hydrophilic layer
CN114805527A (en)2014-05-212022-07-29哈佛大学的校长及成员们 RAS inhibitory peptides and their uses
CA2955357A1 (en)2014-07-172016-01-21The Regents Of The University Of CaliforniaSelf-annealing microgel particles for biomedical applications
CA2961258A1 (en)2014-09-242016-03-31Aileron Therapeutics, Inc.Peptidomimetic macrocycles and uses thereof
BR112017005736A2 (en)2014-09-242017-12-12Aileron Therapeutics Inc peptidomimetic macrocycles and formulations thereof
CN107206119B (en)2014-12-092021-01-29实体科学公司Medical device coating with biocompatible layer
AU2016232833A1 (en)2015-03-182017-10-12Dana-Farber Cancer Institute, Inc.Selective Mcl-1 binding peptides
MX2017011834A (en)2015-03-202018-04-11Aileron Therapeutics IncPeptidomimetic macrocycles and uses thereof.
WO2016183296A1 (en)2015-05-122016-11-17Incept, LlcDrug delivery from hydrogels
WO2017004548A1 (en)2015-07-012017-01-05Aileron Therapeutics, Inc.Peptidomimetic macrocycles
MX2017016251A (en)2015-07-022018-04-20Dana Farber Cancer Inst IncStabilized anti-microbial peptides.
US11078246B2 (en)2015-08-282021-08-03Dana-Farber Cancer Institute, Inc.Peptides binding to Bfl-1
CN108368161A (en)2015-09-102018-08-03艾瑞朗医疗公司Peptidomimetic macrocyclic compound as MCL-1 conditioning agents
JP6184462B2 (en)*2015-10-282017-08-23ウェルズ ファーゴ バンク ナショナル アソシエイション Heterobifunctional polyethylene glycol derivatives and methods for their preparation
WO2017142879A1 (en)2016-02-162017-08-24The Regents Of The University Of CaliforniaMethods for immune system modulation with microporous annealed particle gels
CA3014442A1 (en)2016-02-292017-09-08Dana-Farber Cancer Institute, Inc.Stapled intracellular-targeting antimicrobial peptides to treat infection
US11198715B2 (en)2016-07-222021-12-14Massachusetts Institute Of TechnologySelective Bfl-1 peptides
JP7069126B2 (en)2016-08-262022-05-17デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド BCL-W polypeptides and mimetics for the treatment or prevention of chemotherapy-induced peripheral neuropathy and deafness
JP7042053B2 (en)2016-10-072022-03-25国立大学法人東京工業大学 Branched heteromonodisperse polyethylene glycol, its production method, and its conjugate
CN110446508A (en)2016-12-292019-11-12泰普治疗公司For treating the method and system at medical implant position
WO2018170299A1 (en)2017-03-152018-09-20The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesInhibitors of prokaryotic gene transcription and uses thereof
JP6361083B2 (en)*2017-06-272018-07-25ウェルズ ファーゴ バンク ナショナル アソシエイション Heterobifunctional polyethylene glycol derivatives and methods for their preparation
US11325955B2 (en)2017-07-192022-05-10Dana-Farber Cancer Institute, Inc.Stabilized anti-microbial peptides for the treatment of antibiotic-resistant bacterial infections
WO2019118893A1 (en)2017-12-152019-06-20Dana-Farber Cancer Institute, Inc.Stabilized peptide-mediated targeted protein degradation
JP7575944B2 (en)2017-12-152024-10-30デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド Selective targeting of apoptotic proteins with structure-stabilizing and/or cysteine-responsive NOXA peptides
CA3089279A1 (en)2018-02-072019-08-15Dana-Farber Cancer Institute, Inc.Cell-permeable stapled peptide modules for cellular delivery
EP3765852A1 (en)2018-03-142021-01-20Dana Farber Cancer Institute, Inc.Stabilized peptides for biomarker detection
JP6500318B2 (en)*2018-04-042019-04-17ウェルズ ファーゴ バンク ナショナル アソシエイション Heterobifunctional polyethylene glycol derivative and method for preparing the same
EP3852783A1 (en)2018-09-172021-07-28Massachusetts Institute of TechnologyPeptides selective for bcl-2 family proteins
EP3873435A4 (en)*2018-11-022022-11-09Bionaut Labs Ltd.Magnetomechanic triggering of payload release from miniaturized devices
EP3962933A1 (en)2019-04-182022-03-09Dana-Farber Cancer Institute, Inc.Selective targeting of ubiquitin- and ubiquitin-like e1-activating enzymes by structurally-stabilized peptides
BR112022003689A2 (en)*2019-08-292022-05-24Douglas Godfrin Paul hydrogel matrix
CN114885599A (en)*2019-10-082022-08-09因库博实验室有限责任公司Controlled release formulation delivery device
AU2020404876A1 (en)2019-12-162022-07-21Dana-Farber Cancer Institute, Inc.Structurally-stabilized oncolytic peptides and uses thereof
CA3162922A1 (en)2019-12-202021-06-24Dana-Farber Cancer Institute, Inc.Structurally-stabilized glucagon-like peptide 1 peptides and uses thereof
US20240124529A1 (en)2020-03-042024-04-18Dana-Farber Cancer Institute, Inc.ANTIVIRAL STRUCTURALLY-STABILIZED SARS-CoV-2 PEPTIDES AND USES THEREOF
US20240131124A1 (en)2020-04-222024-04-25Dana-Farber Cancer Institute, Inc.Antiviral structurally-stabilized ace2 helix 1 peptides and uses thereof
CA3179873A1 (en)2020-04-272021-11-04Dana-Farber Cancer Institute, Inc.Structurally-stabilized and hdmx-selective p53 peptides and uses thereof
WO2022081827A1 (en)2020-10-142022-04-21Dana-Farber Cancer Institute, Inc.Chimeric conjugates for degradation of viral and host proteins and methods of use
WO2022098848A1 (en)2020-11-052022-05-12Dana-Farber Cancer Institute, Inc.Antiviral structurally-stabilized ebolavirus peptides and uses thereof
MX2024002824A (en)2021-09-082024-06-28Dana Farber Cancer Inst Inc STRUCTURALLY STAPLED SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2)-CHOLESTEROL PEPTIDE ANTIVIRAL CONJUGATES AND THEIR USES.
EP4518900A1 (en)2022-05-042025-03-12Dana-Farber Cancer Institute, Inc.Ebolavirus surface glycoprotein peptides, conjugates, and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3149006A (en)1963-01-311964-09-15William T AbelPrevention of embrittlement of metals
US3419006A (en)1966-08-081968-12-31Union Carbide CorpNovel dressing and use thereof
US4179337A (en)1973-07-201979-12-18Davis Frank FNon-immunogenic polypeptides
US3963805A (en)1974-10-301976-06-15Union Carbide CorporationWater swellable poly(alkylene oxide)
EP0016652B1 (en)1979-03-211985-08-21National Research Development CorporationComposition for the controlled release of an active substance and process for its preparation
JPS585320A (en)1981-07-011983-01-12Toray Ind IncGraft copolymer
EP0206448B1 (en)1985-06-191990-11-14Ajinomoto Co., Inc.Hemoglobin combined with a poly(alkylene oxide)
WO1992000748A1 (en)1990-07-061992-01-23Enzon, Inc.Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
IE912365A1 (en)1990-07-231992-01-29Zeneca LtdContinuous release pharmaceutical compositions
US5410016A (en)1990-10-151995-04-25Board Of Regents, The University Of Texas SystemPhotopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5626863A (en)1992-02-281997-05-06Board Of Regents, The University Of Texas SystemPhotopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5192743A (en)1992-01-161993-03-09Genentech, Inc.Reconstitutable lyophilized protein formulation
US5573934A (en)1992-04-201996-11-12Board Of Regents, The University Of Texas SystemGels for encapsulation of biological materials
US5334640A (en)1992-04-081994-08-02Clover Consolidated, Ltd.Ionically covalently crosslinked and crosslinkable biocompatible encapsulation compositions and methods
WO1993024476A1 (en)1992-06-041993-12-09Clover Consolidated, LimitedWater-soluble polymeric carriers for drug delivery
US5514379A (en)1992-08-071996-05-07The General Hospital CorporationHydrogel compositions and methods of use
AU4899093A (en)1992-10-131994-04-28Pacesetter AbCompound and method of applying anti-fouling coatings on medical devices
US5321095A (en)1993-02-021994-06-14Enzon, Inc.Azlactone activated polyalkylene oxides
DE4342154A1 (en)1993-12-101995-06-14Behringwerke Ag Amidinophenylalanine derivatives, process for their preparation, their use and agents containing them as anticoagulants
US5618528A (en)1994-02-281997-04-08Sterling Winthrop Inc.Biologically compatible linear block copolymers of polyalkylene oxide and peptide units
US5730968A (en)1994-03-311998-03-24Sterling Winthrop Inc.Segmented chelating polymers as imaging and therapeutic agents
EP0802787A4 (en)*1994-06-171998-09-02Univ Nebraska IN SITU YELLOWING SUBSTANCE FOR THE ADMINISTRATION OF BIOACTIVE SUBSTANCES AND METHODS OF USE
WO1996020012A2 (en)1994-12-231996-07-04Middlesex Sciences, Inc.Methods for preparing and purifying macromolecular conjugates
US5962023A (en)*1995-03-061999-10-05Ethicon, Inc.Hydrogels containing absorbable polyoxaamides
US5698213A (en)*1995-03-061997-12-16Ethicon, Inc.Hydrogels of absorbable polyoxaesters
US5648088A (en)1995-03-061997-07-15Ethicon, Inc.Blends of absorbable polyoxaesters containing amines and/or amide groups
US5607687A (en)1995-03-061997-03-04Ethicon, Inc.Polymer blends containing absorbable polyoxaesters
US5597579A (en)1995-03-061997-01-28Ethicon, Inc.Blends of absorbable polyoxaamides
DK2111876T3 (en)1995-12-182011-12-12Angiodevice Internat Gmbh Crosslinked polymer preparations and methods for their use
US5610241A (en)1996-05-071997-03-11Cornell Research Foundation, Inc.Reactive graft polymer with biodegradable polymer backbone and method for preparing reactive biodegradable polymers
US6214966B1 (en)1996-09-262001-04-10Shearwater CorporationSoluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US6258351B1 (en)1996-11-062001-07-10Shearwater CorporationDelivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
EP1053019B1 (en)1998-01-072003-12-03Debio Recherche Pharmaceutique S.A.Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom
US6348558B1 (en)1999-12-102002-02-19Shearwater CorporationHydrolytically degradable polymers and hydrogels made therefrom

Cited By (38)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20030202955A1 (en)*1996-11-062003-10-30Debio Recherche Pharmaceutique S.A.Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
US7018624B2 (en)1996-11-062006-03-28Debio Recherche Pharmaceutique S.A.Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
US8802146B2 (en)*1998-11-062014-08-12Neomend, Inc.Systems, methods, and compositions for prevention of tissue adhesion
US20070213683A1 (en)*1998-11-062007-09-13Neomend, Inc.Systems, methods, and compositions for prevention of tissue adhesion
US20100099852A1 (en)*1998-11-062010-04-22Neomend, Inc.Systems, methods, and compositions for prevention of tissue adhesion
US8642085B2 (en)*1998-11-062014-02-04Neomend, Inc.Systems, methods, and compositions for prevention of tissue adhesion
US7695910B2 (en)2001-09-012010-04-13Samsung Electronics Co., Ltd.Method for manufacturing hydrogel biochip by using star-like polyethylene glycol derivative having epoxy group
US20070020676A1 (en)*2001-09-012007-01-25Nam HuhMethod for manufacturing hydrogel biochip by using star-like polyethylene glycol derivative having epoxy group
US20030108917A1 (en)*2001-09-012003-06-12Nam HuhMethod for manufacturing hydrogel biochip by using star-like polyethylene glycol derivative having epoxy group
US8609080B2 (en)2001-12-142013-12-17The University Of WyomingMethods and compositions for controlled release of drugs
US8105570B2 (en)2001-12-142012-01-31The University Of WyomingMethods and compositions for controlled release of drugs
US20090264600A1 (en)*2002-09-092009-10-22Nektar Therapeutics Al, CorporationMethod for Preparing Water-Soluble Polymer Derivatives Bearing a Terminal Carboxylic Acid
US7569214B2 (en)2002-09-092009-08-04Nektar Therapeutics Al, CorporationMethod for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid
KR100967334B1 (en)2002-09-092010-07-05넥타르 테라퓨틱스 Process for the preparation of water soluble polymer derivatives with terminal carboxylic acids
US9045494B2 (en)2002-09-092015-06-02Nektar TherapeuticsOrthoester compound
US8182801B2 (en)2002-09-092012-05-22Nektar TherapeuticsMethod for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid
WO2004022629A3 (en)*2002-09-092004-04-08Nektar Therapeutics Al CorpMethod for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid
US8435504B2 (en)2002-09-092013-05-07Nektar TherapeuticsMethod for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid
US8784791B2 (en)2002-09-092014-07-22Nektar TherapeuticsMethod for preparing water-soluble polymer derivatives bearing an N-succinimidyl ester
WO2004022629A2 (en)*2002-09-092004-03-18Nektar Therapeutics Al, CorporationMethod for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid
US20040231886A1 (en)*2003-05-202004-11-25Boggs David W.PCB design and method for providing vented blind vias
US20100268750A1 (en)*2007-11-082010-10-21Koninklijke Philips Electronics N.V.Method and electronic device for managing content
US20090215923A1 (en)*2008-02-132009-08-27Hyperbranch Medical Technology, Inc.Crosslinked Polyalkyleneimine Hydrogels with Tunable Degradation Rates
US8410189B2 (en)2008-02-132013-04-02Hyperbranch Medical Technology, Inc.Crosslinked polyalkyleneimine hydrogels with tunable degradation rates
US8846022B2 (en)2008-02-132014-09-30Hyperbranch Medical Technology, Inc.Crosslinked polyalkyleneimine hydrogels with tunable degradation rates
US20110044932A1 (en)*2008-02-132011-02-24Hyperbranch Medical Technology, Inc.Crosslinked Polyalkyleneimine Hydrogels with Tunable Degradation Rates
US8440309B2 (en)2011-01-312013-05-14Confluent Surgical, Inc.Crosslinked polymers with the crosslinker as therapeutic for sustained release
US8889889B2 (en)2011-01-312014-11-18Confluent Surgical, Inc.Crosslinked polymers with the crosslinker as therapeutic for sustained release
US10806144B2 (en)2011-11-032020-10-20The Trustees Of Columbia University In The City Of New YorkComposition with sustained antimicrobial activity
US20150202305A1 (en)*2012-09-072015-07-23The Regents Of The University Of CaliforniaMethod of creating hydrogels through oxime bond fomration
US10201613B2 (en)*2012-09-072019-02-12The Regents Of The University Of CaliforniaMethod of creating hydrogels through oxime bond formation
US9061137B2 (en)*2012-10-102015-06-23Korea Institute Of Science And TechnologyNerve electrode provided with anti-inflammatory drug and method of manufacturing the same
US9855340B2 (en)2012-10-112018-01-02Ascendis Pharma A/SHydrogel prodrugs
US11041052B2 (en)2016-03-312021-06-22Nof CorporationBiodegradable hydrogel having cyclic benzylidene acetal structure
WO2017200818A1 (en)*2016-05-162017-11-23The Trustees Of Columbia University In The City Of New YorkCoatings and methods for infection-resistant medical devices
US20210162092A1 (en)*2018-08-102021-06-03Shanghai Ruining Biotechnology Co. LtdMedical hydrogel
WO2022170681A1 (en)*2021-02-092022-08-18北京光瓴医疗科技有限公司Degradable two-component hydrogel, preparation method therefor and use thereof
CN114767920A (en)*2022-05-132022-07-22中国科学院长春应用化学研究所 A kind of polyethylene glycol based adhesive and its preparation method and application

Also Published As

Publication numberPublication date
EP1019446B1 (en)2007-03-28
ES2281925T3 (en)2007-10-01
AU6029398A (en)1999-04-05
ES2281925T5 (en)2012-04-13
DE69837443T3 (en)2012-05-24
CA2303365A1 (en)1999-03-25
EP1019446B2 (en)2011-11-30
JP4083384B2 (en)2008-04-30
PT1019446E (en)2007-06-25
EP1019446A1 (en)2000-07-19
JP2001518528A (en)2001-10-16
ATE358150T1 (en)2007-04-15
DE69837443D1 (en)2007-05-10
WO1999014259A1 (en)1999-03-25
CA2303365C (en)2007-08-21
US20040076602A1 (en)2004-04-22
DK1019446T3 (en)2007-07-30
US7964217B2 (en)2011-06-21
DK1019446T4 (en)2012-03-19
DE69837443T2 (en)2008-04-17

Similar Documents

PublicationPublication DateTitle
US7964217B2 (en)Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
US7018624B2 (en)Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
US7214388B2 (en)Degradable heterobifunctional poly(ethylene glycol) acrylates
JP2003518526A (en) Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
AU2002328388B2 (en)Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor

Legal Events

DateCodeTitleDescription
ASAssignment

Owner name:SHEARWATER POLYMERS, INC., ALABAMA

Free format text:ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HARRIS, J. MILTON;REEL/FRAME:009092/0502

Effective date:19980305

ASAssignment

Owner name:SHEARWATER CORPORATION, ALABAMA

Free format text:CHANGE OF NAME;ASSIGNOR:SHEARWATER POLYMERS, INC.;REEL/FRAME:011295/0671

Effective date:20000927

ASAssignment

Owner name:DEBIO RECHERCHE PHARMACEUTIQUE S.A., SWITZERLAND

Free format text:ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SHEARWATER POLYMERS, INC.;REEL/FRAME:011702/0600

Effective date:20001114

ASAssignment

Owner name:NEKTAR THERAPEUTICS AL, CORPORATION, ALABAMA

Free format text:CHANGE OF NAME;ASSIGNOR:SHEARWATER CORPORATION;REEL/FRAME:013467/0564

Effective date:20021202

ASAssignment

Owner name:NEKTAR THERAPEUTICS AL, CORPORATION, ALABAMA

Free format text:RE-RECORD TO REMOVE SIX APPLICATION AND PATENT NUMBERS INCORRECTLY INCLUDED ON PREVIOUSLY RECORDED DOCUMENT AT REEL 013467 FRAME 0564.;ASSIGNOR:SHEARWATER CORPORATION;REEL/FRAME:014186/0610

Effective date:20021202

STCBInformation on status: application discontinuation

Free format text:ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

ASAssignment

Owner name:NEKTAR THERAPEUTICS, CALIFORNIA

Free format text:MERGER;ASSIGNOR:NEKTAR THERAPEUTICS AL, CORPORATION;REEL/FRAME:023196/0394

Effective date:20090731

Owner name:NEKTAR THERAPEUTICS,CALIFORNIA

Free format text:MERGER;ASSIGNOR:NEKTAR THERAPEUTICS AL, CORPORATION;REEL/FRAME:023196/0394

Effective date:20090731


[8]ページ先頭

©2009-2025 Movatter.jp